199 related articles for article (PubMed ID: 33675070)
21. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
[TBL] [Abstract][Full Text] [Related]
22. The Munich-Transarterial Chemoembolisation Score Holds Superior Prognostic Capacities Compared to TACE-Tailored Modifications of 9 Established Staging Systems for Hepatocellular Carcinoma.
Op den Winkel M; Nagel D; Op den Winkel P; Paprottka PM; Schmidt L; Bourhis H; Trojan J; Goeller M; Reiter FP; Stecher SS; De Toni EN; Gerbes AL; Kolligs FT
Digestion; 2019; 100(1):15-26. PubMed ID: 30282074
[TBL] [Abstract][Full Text] [Related]
23. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Park C; Kim JH; Kim PH; Kim SY; Gwon DI; Chu HH; Park M; Hur J; Kim JY; Kim DJ
Korean J Radiol; 2021 Feb; 22(2):213-224. PubMed ID: 32901464
[TBL] [Abstract][Full Text] [Related]
24. Alanine aminotransferase to hemoglobin ratio is an indicator for disease progression for hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization.
Lin ZH; Li X; Hong YF; Ma XK; Wu DH; Huang M; Chen ZH; Chen J; Dong M; Wei L; Wang TT; Ruan DY; Lin ZX; Zhong X; Xing YF; Wen JY; Wu XY; Lin Q
Tumour Biol; 2016 Mar; 37(3):2951-9. PubMed ID: 26411670
[TBL] [Abstract][Full Text] [Related]
25. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
26. Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma.
English K; Brodin NP; Shankar V; Zhu S; Ohri N; Golowa YS; Cynamon J; Bellemare S; Kaubisch A; Kinkhabwala M; Kalnicki S; Garg MK; Guha C; Kabarriti R
JAMA Netw Open; 2020 Nov; 3(11):e2023942. PubMed ID: 33151315
[TBL] [Abstract][Full Text] [Related]
27. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients.
Chen L; Ni CF; Chen SX; Cao JM; Zhu HD; Guo JH; Zhu GY; Zhong BY; Ding W; He SC; Deng G; Teng GJ
J Vasc Interv Radiol; 2016 Sep; 27(9):1288-1297. PubMed ID: 27013402
[TBL] [Abstract][Full Text] [Related]
28. A prediction model for overall survival after transarterial chemoembolization for hepatocellular carcinoma invading the hepatic vein or inferior vena cava.
Chu HH; Chun SY; Kim JH; Kim PH; Il Gwon D; Ko HK; Kim N
Eur Radiol; 2021 Jun; 31(6):4232-4242. PubMed ID: 33241523
[TBL] [Abstract][Full Text] [Related]
29. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
30. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
Nabavizadeh N; Jahangiri Y; Rahmani R; Tomozawa Y; Geeratikun Y; Chen Y; Hung A; Degnin C; Farsad K
AJR Am J Roentgenol; 2021 Sep; 217(3):691-698. PubMed ID: 32997517
[No Abstract] [Full Text] [Related]
31. A prognostic score model for predicting the survival benefits of patients undergoing sorafenib plus transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion.
Li JR; Wu MJ; Wang T; Tian M; Zhou G; Liu QX; Xiang XH; Zhang YQ
Abdom Radiol (NY); 2021 May; 46(5):1967-1976. PubMed ID: 33386450
[TBL] [Abstract][Full Text] [Related]
32. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
[TBL] [Abstract][Full Text] [Related]
33. Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3-5cm: A propensity score matching study.
Li M; He J; Pan M; Yu Y; Pan Z; Xu B; Zhu J
Dig Liver Dis; 2016 Sep; 48(9):1082-7. PubMed ID: 27365224
[TBL] [Abstract][Full Text] [Related]
34. Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization.
Gu J; Zhang X; Cui R; Zhang J; Wang Z; Jia Y; Miao R; Dong Y; Ma X; Fan H; Wang H; Ren L; Li Y; Niu W; Zhang J; Qu K; Liu C
Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):836-844. PubMed ID: 30614882
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Survival Factors of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Rohan T; Uher M; Matkulčík P; Zavadil J; Ostřížková L; Kiss I; Andrašina T; Válek V
Klin Onkol; 2020; 33(3):214-219. PubMed ID: 32683878
[TBL] [Abstract][Full Text] [Related]
36. Low Psoas-Muscle index is associated with decreased survival in hepatocellular carcinoma treated with transarterial chemoembolization.
Zhang JX; Yan HT; Ding Y; Liu J; Liu S; Zu QQ; Shi HB
Ann Med; 2022 Dec; 54(1):1562-1569. PubMed ID: 35639492
[TBL] [Abstract][Full Text] [Related]
37. Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study.
Pinato DJ; Arizumi T; Jang JW; Allara E; Suppiah PI; Smirne C; Tait P; Pai M; Grossi G; Kim YW; Pirisi M; Kudo M; Sharma R
Oncotarget; 2016 Jul; 7(28):44705-44718. PubMed ID: 27244889
[TBL] [Abstract][Full Text] [Related]
38. Predicting Survival Using Pretreatment CT for Patients With Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: Comparison of Models Using Radiomics.
Kim J; Choi SJ; Lee SH; Lee HY; Park H
AJR Am J Roentgenol; 2018 Nov; 211(5):1026-1034. PubMed ID: 30240304
[TBL] [Abstract][Full Text] [Related]
39. The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization.
Zhang Y; Miao H; Xie W; Jiang S; Song Z; Huang G; Fan W; Wang Y; Li J; Chen Y
Eur Radiol; 2021 Jan; 31(1):232-243. PubMed ID: 32728770
[TBL] [Abstract][Full Text] [Related]
40. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]